• 제목/요약/키워드: Mucopolysaccharidoses

검색결과 10건 처리시간 0.035초

Diagnosis and Management of Patients with Mucopolysaccharidoses in Malaysia

  • Ngu, Lock-Hock
    • Journal of mucopolysaccharidosis and rare diseases
    • /
    • 제4권1호
    • /
    • pp.11-13
    • /
    • 2018
  • In Malaysia, diagnosis and treatment of patients with mucopolysaccharidoses (MPS) is mainly localized at Hospital Kuala Lumpur, which is the national referral center for rare diseases. To date there are 83 patients diagnosed with MPS in our center, with MPS II being the commonest. The Malaysian National Medicines Policy second edition has a specific section on the orphan drugs which includes recombinant human enzyme for enzyme replacement therapy (ERT) in MPS. So far, National Pharmaceutical Regulatory Agency Malaysia has approved recombinant human enzyme for MPS types I (Loranidase), II (idursulfase), IVA (elosulfase alfa), and VI (Galsufase). Access to Idursulfase beta (another recombinant human enzyme for MPS II) and vestronidase alfa-vjbk (MPS VII) required special authorization on named patient basic. Currently there are 25 patients receiving ERT, 70% of the funding are from Ministry of Health (MOH), the remaining 30% are from various charitable funds and humanitarian programs. Thirteen newly diagnosed patients have to queue for an additional fund. Four patients have been treated with Hematopoietic stem cell transplant. MOH has also published guidelines regarding the patient selection criteria for ERT and treatment monitoring schedule.

Newborn Screening of Lysosomal Storage Diseases, Including Mucopolysaccharidoses

  • Kim, Su Jin
    • Journal of mucopolysaccharidosis and rare diseases
    • /
    • 제3권1호
    • /
    • pp.9-13
    • /
    • 2017
  • Tandem mass spectrometry and other new technologies for the multiplex and quantitative analysis of dried blood spots have emerged as powerful techniques for the early screening and assessment of newborns for lysosomal storage diseases (LSDs). Screening newborns for these diseases is important, since treatment options, including enzyme replacement therapy or hematopoietic transplantation, are available for some LSDs, such as infant-onset Pompe disease, Fabry disease, some types of mucopolysaccharidoses (MPSs), and Krabbe disease. For these diseases, early initiation of treatment, before symptoms worsen, often leads to better clinical outcomes. Several problems, however, are associated with newborn screening for LSDs, including the development of accurate test methods to reduce low false-positive rates and treatment guidelines for late-onset or mild disease variants, the high costs associated with multiplex assays, and ethical issues. In this review, we discuss the history, current status, and ethical problems associated with the newborn screening for LSDs, including MPSs.

선천성 대사 이상 질환에서의 골격계 증상 발현 (Skeletal Manifestations of Inborn Errors of Metabolism: A Comprehensive Retrospect)

  • 조성윤
    • 대한유전성대사질환학회지
    • /
    • 제23권1호
    • /
    • pp.1-11
    • /
    • 2023
  • Inborn errors of metabolism encompass a wide variety of disorders, frequently affecting bone. This review presents a comprehensive retrospect on the primary involvement of bone in inborn errors of metabolism. Primary involvement of bone in inborn errors of metabolism includes entities that primarily affect the bone marrow, mineral component or cartilage. These include lysosomal storage disorders, hypophosphatasia, and hereditary hypophosphatemic rickets. In this review, we discuss the primary involvement of bone in inborn errors of metabolism (hypophosphatasia, X-linked hypophosphatemic rickets, Gaucher disease, and mucopolysaccharidoses) along with the therapeutic agents used in clinical settings, diagnostic strategies, and general management. With the development of disease-specific targeted therapies and supportive care, more number of patients with these disorders live longer and survive into adulthood. Moreover, skeletal symptoms have become a more prominent feature of these disorders. This makes the awareness of these skeletal symptoms more important.

  • PDF

Mucopolysaccharidoses in Taiwan

  • Lin, Hsiang-Yu;Chuang, Chih-Kuang;Lin, Shuan-Pei
    • Journal of mucopolysaccharidosis and rare diseases
    • /
    • 제4권1호
    • /
    • pp.14-20
    • /
    • 2018
  • Mucopolysaccharidoses (MPSs) are a group of rare inherited metabolic disorders caused by specific lysosomal enzyme deficiencies leading to the sequential degradation of glycosaminoglycans, causing substrate accumulation in various cells and tissues and progressive multiple organ dysfunction. The rare disease medical care team at Mackay Memorial Hospital in Taiwan has been dedicated to the study of MPSs for more than 20 years. Since 1999, more than 50 academic papers focusing on MPSs have been published in international medical journals. Topics of research include the following items regarding MPSs: incidence, natural history, clinical manifestations, gene mutation characteristics, cardiac function, bone mineral density, sleep studies, pulmonary function tests, hearing assessments, percutaneous endoscopic gastrostomy, anesthetic experience, imaging analysis, special biochemical tests, laboratory diagnostics, global expert consensus conferences, prenatal diagnosis, new drug clinical trials, newborn screening, and treatment outcomes. Of these published academic research papers, more than half were cross-domain, cross-industry, and international studies with results in cooperation with experts from European, American and other Asian countries. A cross-specialty collaboration platform was established based on high-risk population screening criteria with the acronym "BECARE" (Bone and joints, Eyes, Cardiac and central nervous system, Abdomen and appearance, Respiratory system, and Ear, nose, and throat involvement). Through this platform, orthopedic surgeons, rheumatologists, ophthalmologists, cardiologists, rehabilitation physicians, gastroenterologists, otorhinolaryngologists, and medical geneticists have been educated with regards to awareness of suspected cases of MPSs patients to allow for a further confirmative diagnosis of MPSs. Because of the progressive nature of the disease, an early diagnosis and early multidisciplinary therapeutic interventions including surgery, rehabilitation programs, symptom-based treatments, hematopoietic stem cell transplantation, and enzyme replacement therapy, are very important.

GLB1-related disorders: GM1 gangliosidosis and Morquio B disease

  • Cho, Sung Yoon;Jin, Dong-Kyu
    • Journal of Genetic Medicine
    • /
    • 제18권1호
    • /
    • pp.16-23
    • /
    • 2021
  • GLB1-related disorders comprise two phenotypically unique disorders: GM1 gangliosidosis and Morquio B disease. These autosomal recessive disorders are caused by b-galactosidase deficiency. A hallmark of GM1 gangliosidosis is central nervous system degeneration where ganglioside synthesis is highest. The accumulation of keratan sulfate is the suspected cause of the bone findings in Morquio B disease. GM1 gangliosidosis is clinically characterized by a neurodegenerative disorder associated with dysostosis multiplex, while Morquio B disease is characterized by severe skeletal manifestations and the preservation of intelligence. Morquio B disease and GM1 gangliosidosis may be on a continuum of skeletal involvement. There is currently no effective treatment for GLB1-related disorders. Recently, multiple interventions have been developed and there are several ongoing clinical trials.

한국 뮤코 다당체 침착증 환자에 대한 임상적 고찰 (Clinical and Laboratory Features of Korean Mucopolysaccharidoses (MPSs))

  • 손우연;이지현;백경훈;권은경;김안희;진동규
    • Clinical and Experimental Pediatrics
    • /
    • 제48권10호
    • /
    • pp.1132-1138
    • /
    • 2005
  • 목 적 : 뮤코 다당체 침착증은 glycosaminoglycan을 분해하는 라이소솜 효소의 유전적 결핍에 의해 라이소솜에 전구 물질이 축적되는 질환군이다. 임상 양상은 매우 다양하지만, 일반적으로 만성적이고 진행되는 경과를 보이며 투박한 얼굴 모양, 관절의 경직, 간비 비대, 성장 지연, 신경학적 퇴화를 특징으로 한다. 최근 뮤코 다당체 침착증 I형의 효소 대체 요법이 가능하며 곧 II형에서도 실용화될 전망이다. 임상 증상이 나타나기 전에 효소 치료를 시작함으로써, 뮤코 다당체 침착증 환자에서 보이는 신경학적 및 근골격계 퇴행의 예방이 가능할 것으로 기대하고 있으며, 이에 조기 진단이 더욱 강조되고 있는 상황이다. 저자들은 본원 뮤코 다당체 침착증 환아 모임에 가입된 환아 80명을 대상으로 임상 양상을 분석하여, 국내 뮤코 다당체 환아들의 임상양상을 연구하고자 하였다. 방 법 : 1995년 2월부터 2004년 12월까지 삼성서울병원 소아과를 방문한 환아 중, 피부 섬유아세포 배양 효소 검사에 의해 뮤코 다당체 침착증이 확진된 환아 80명을 대상으로 하였다. 입원기록 및 외래기록을 검토하여 진단시 연령과 성별, 가족력, 이학적 특징, 방사선 검사, 이비인후과 검사, 안과 검사, 지능검사, 언어 평가에 대한 결과를 분석하였다. 결 론 : 유형별로 II형이 51명(64%), III형이 14명(17.5%), I형이 12명(15%), IV형이 3명(3.8%)으로 II형의 빈도가 월등히 높았다. 진단시 연령은 1세부터 20까지 있었으며, 평균 5.5세였다. 남녀비는 4.7:1이였고, II형 헌터 증후군 51명은 모두 남아였다. 부모가 환아에서 이상을 느낀 첫 징후는 발달 지연이 12례(17%)로 가장 많았고, 그 외에 언어 발달지연(17%), 외모의 이상(16%), 관절 경직(14%) 등이 있었다. 방사선 검사상 전형적인 골격계 변화가 45례(83%)에서 관찰되었다. 55례에서 심장 초음파 검사를 시행했는데 판막의 비후와 경한 역류 소견이 많았고 특히 승모판막의 비후와 역류가 각각 46례(82%), 31례(55%)로 가장 빈번하였다. 이비인후과 평가를 받은 63례 중 46례(73%)에서 중이저류가 관찰되었고, 28례의 환아는 환기관 삽입을 시행 받았다. 33례(82%)에서 중등도 이상의 청력소실이 있었고, 특히 II형 환아들의 ABR 역치 평균이 66.9로 가장 높았다. 지능검사가 가능했던 35례의 환아 중에서 중등도 이상의 정신 지체가 14례(56%)였다. II형 51례의 환아 중에서 4명이 HLA 일치되는 형제로부터 골수이식을 받았다. 그 중 1명은 이식편대 숙주 반응 합병증으로 사망하였고, 나머지 3명에서도 신경학적 퇴행을 예방하지 못하였다. 현재 5명의 I형 환아들에서 효소 대체 치료를 시작하였고 이들의 임상 경과를 주목하고 있다. 결 론 : 본 연구에서는 80명의 뮤코 다당체 침착증 환자를 대상으로 임상 양상을 분석하였고 유형별로는 II형 헌터 증후군의 빈도가 64%로 외국 연구에 비해 월등히 높았으며 이는 인구학적 차이를 반영한다고 사료된다. 발달 지연, 저신장, 근골격계 변화, 심장판막 변화, 정신 지체, 청력 소실 등 뮤코 다당체 침착증의 전형적인 증상들이 환아의 대부분에서 관찰되었다. 저자들은 국내 뮤코 다당체 침착증 환아들의 임상적 양상을 연구함으로써 조기 진단과 적절한 치료를 하는데 도움이 되고자 하였다.

Enzyme Replacement Therapy for Lysosomal Storage Disease in Indonesia

  • Sjarif, Damayanti Rusli;Hafifah, Cut Nurul
    • Journal of mucopolysaccharidosis and rare diseases
    • /
    • 제4권1호
    • /
    • pp.7-10
    • /
    • 2018
  • Rare diseases are life threatening or chronically debilitating diseases with a low prevalence (less than 2,000 people in a population), which includes lysosomal storage diseases. These diseases are often seen as unimportant especially in developing countries, such as Indonesia, due to small number of patients. National Rare Disease Center in Indonesia was pioneered almost 20 years ago and officially established in 2017 by the Indonesian Minister of Health. Lysosomal storage disease become the most commonly found inborn errors of metabolism (IEM) in Indonesia due to easily accessible diagnostic facilities. Currently there are 7 patients receiving ERT in this mixed-donation scheme, one patient with Gaucher disease and 6 patients with MPS type II. Few challenges for ERT in Indonesia include importation through special access scheme, preparation of ERT infusion in intensive care settting, and cost of treatment. Even with limited resources, healthcare professionals in Indonesia have been giving the best care possible for rare disease patients, especially to provide diagnostic facilities through collaboration and treatment options for treatable rare diseases. Improvements in care for rare disease patients are still needed.

뮤코다당증의 장기 치료 효과와 한계점 극복을 위한 노력

  • 손영배
    • 대한유전성대사질환학회지
    • /
    • 제14권1호
    • /
    • pp.29-36
    • /
    • 2014
  • Mucopolysaccharidoses (MPSs) are a group of rare inherited metabolic diseases caused by deficiency of lysosomal enzymes. MPSs are clinically heterogeneous and characterized by progressive deterioration in visceral, skeletal and neurological functions. The aim of this article is to review the treatment of MPSs, the unmet needs of current treatments and vision for the future including recent clinical trials. Until recently, supportive care was the only option available for the management of MPSs. Hematopoietic stem cell transplantation (HSCT), another potentially curative treatment, is not routinely advocated in clinical practice due to its high risk profile and lack of evidence for efficacy. From the early 2000s, enzyme replacement therapy (ERT) was approved and available for the treatment of MPS I, II and VI. ERT is effective for the treatment of many somatic symptoms, particularly walking ability and respiratory function, and remains the mainstay of MPS treatment. However, no benefit was found in the neurological symptoms because the enzymes do not readily cross the blood-brain barrier (BBB). In recent years, intrathecal (IT) ERT, substrate reduction therapy (SRT) and gene therapy have been rapidly gaining greater recognition as potential therapeutic avenues. Although still under investigation, IT ERT, SRT and gene therapy are promising MPS treatments that may prevent the neurodegeneration not improved by ERT.

Growth hormone treatment for children with mucopolysaccharidosis I or II

  • Minji Im;Chiwoo Kim;Juyoung Sung;Insung Kim;Ji-Hoon Hwang;Min-Sun Kim;Sung Yoon Cho
    • Journal of Genetic Medicine
    • /
    • 제20권2호
    • /
    • pp.60-69
    • /
    • 2023
  • Purpose: Despite enzyme replacement therapy (ERT) and/or allogeneic hematopoietic stem cell transplantation, individuals with mucopolysaccharidosis (MPS) I or II often experience significant growth deficiencies. This study aimed to assess the safety and efficacy of recombinant human growth hormone (hGH) treatment in children diagnosed with MPS I or II. Materials and Methods: A total of nine pediatric patients-four with MPS I and five with MPS II-underwent treatment with ERT and hGH at Samsung Medical Center. Results: The mean hGH dose administered was 0.26±0.03 mg/kg/week. In the MPS I group, three patients showed an increase in height Z-score from -4.09±0.83 to -3.68±0.43 after 1 year of hGH treatment, and to -3.10±0.72 by the end of the hGH regimen. In the MPS II group, while the height Z-score of four patients decreased according to standard growth charts, it improved from 1.61±1.79 to 2.71±1.68 based on the disease-specific growth chart through hGH treatment. Two patients discontinued hGH treatment due to lack of efficacy after 22 and 6 months each of treatment, respectively. No new-onset neurological symptoms or necessity for prosthetic or orthopedic surgery were reported during hGH treatment. Conclusion: This study provides insights into the impact of hGH on MPS patients, demonstrating its potential to reverse growth deceleration in some cases. Further research is needed to explore the long-term effects of hGH on changes in body composition, muscle strength, and bone health in this population.

양악 편측에 발생한 다발성 함치성 낭종의 치험례 (TREATMENT FOR IDIOPATHIC MULTIPLE DENTIGEROUS CYSTS: CASE REPORT)

  • 김기백;김선미;양규호;최남기
    • 대한소아치과학회지
    • /
    • 제36권2호
    • /
    • pp.270-274
    • /
    • 2009
  • 함치성 낭종은 일반적으로 미맹출 치아의 치관을 포함하고 있는 형태로, 치아 법랑질과 이장 상피 사이에 액체가 축적되어 생긴 잔존 법랑 상피조직의 퇴행성 변화로 부터 생긴다. 치근단 낭 다음으로 가장 흔한 치성 낭종으로, 주로 단독으로 발생하고 하악 제 3대구치와 상악 소구치에 호발한다. 악골의 다발성 낭종은 주로 기저세포 모반 증후군과 관련된 치성 각화낭이 대부분이고, 점액다당류증 또는 쇄골두개 이형성증과도 관련이 있을 수 있다. 단발성의 함치성 낭종은 우리에게 친숙할 정도로 유병율에서 치료 및 예후까지 잘 알려져 있으나, 전신병력이 없는 다발성의 함치성 낭종은 드물며, 상악과 하악에 발생한 다발성 낭종은 특히 더 드물다. 본 증례는 편측성으로 양악에 함께 발생한 다발성의 함치성 낭종을 가진 11세 소년에 대한 치료 증례로 1년간의 관찰 후 양호할만한 결과를 얻었기에 보고하는 바이다. 1년이라는 관찰 기간이 짧기 때문에 향후 지속적인 임상적, 방사선적 관찰을 필요로 하리라 사료된다.

  • PDF